Nina Wagner-Johnston

Associate Professor - Par

19992018
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 15 Similar Profiles
Lymphoma Medicine & Life Sciences
Non-Hodgkin's Lymphoma Medicine & Life Sciences
oxaliplatin Medicine & Life Sciences
Lymphoma, Large B-Cell, Diffuse Medicine & Life Sciences
Mantle-Cell Lymphoma Medicine & Life Sciences
Hodgkin Disease Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Phosphatidylinositol 3-Kinase Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1999 2018

CALGB 50604: Risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

Straus, D. J., Jung, S. H., Pitcher, B., Kostakoglu, L., Grecula, J. C., Hsi, E. D., Schöder, H., Popplewell, L. L., Chang, J. E., Moskowitz, C. H., Wagner-Johnston, N., Leonard, J. P., Friedberg, J. W., Kahl, B. S., Cheson, B. D. & Bartlett, N. L., Sep 6 2018, In : Blood. 132, 10, p. 1013-1021 9 p.

Research output: Contribution to journalArticle

Hodgkin Disease
Bleomycin
Positron-Emission Tomography
Doxorubicin
Therapeutics

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL

Byrd, J. C., Smith, S., Wagner-Johnston, N., Sharman, J., Chen, A. I., Advani, R., Augustson, B., Marlton, P., Commerford, S. R., Okrah, K., Liu, L., Murray, E., Penuel, E., Ward, A. F. & Flinn, I. W., Jan 1 2018, In : Oncotarget. 9, 16, p. 13023-13035 13 p.

Research output: Contribution to journalArticle

B-Cell Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
Human Influenza
Mutation
Bone Marrow Transplantation
Cyclophosphamide
Tissue Donors
Confidence Intervals
Transplants

Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial

Brown, J. R. , Hamadani, M. , Hayslip, J. , Janssens, A. , Wagner-Johnston, N. , Ottmann, O. , Arnason, J. , Tilly, H. , Millenson, M. , Offner, F. , Gabrail, N. Y. , Ganguly, S. , Ailawadh, S. , Kasar, S. , Kater, A. P. , Doorduijn, J. K. , Gao, L. , Lager, J. J. , Wu, B. , Egile, C. & 1 others Kersten, M. J., Jan 1 2018, (Accepted/In press) In : The Lancet Haematology.

Research output: Contribution to journalArticle

B-Cell Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
Mantle-Cell Lymphoma
Follicular Lymphoma
Safety

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia

Garzon, R., Savona, M., Baz, R., Andreeff, M., Gabrail, N., Gutierrez, M., Savoie, L., Mau-Sorensen, P. M., Wagner-Johnston, N., Yee, K., Unger, T. J., Saint-Martin, J. R., Carlson, R., Rashal, T., Kashyap, T., Klebanov, B., Shacham, S., Kauffman, M. & Stone, R., Jun 15 2017, In : Blood. 129, 24, p. 3165-3174 10 p.

Research output: Contribution to journalArticle

Clinical Trials, Phase I
Acute Myeloid Leukemia
Toxicity
Refractory materials
Hazards